Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of hydrocodone bitartrate
extended-release tablets at doses of 30 to 90 mg every 12 hours compared with placebo in
alleviating moderate to severe pain in patients with chronic low back pain. Patients may be
opioid-naïve or opioid-experienced.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries